人工智能驱动的药物发现公司Recursion Pharmaceuticals和Exscientia正在合并，以加速药物发现。 Recursion Pharmaceuticals and Exscientia, AI-driven drug discovery firms, are merging to accelerate medicine discovery.
人工智能驱动的药物发现公司Recursion Pharmaceuticals和Exscientia已同意合并。 Recursion Pharmaceuticals and Exscientia, AI-powered drug discovery companies, have agreed to merge. 合并公司将保留 " 递归 " 名称,并继续在NASDAQ上进行交易。 The combined company will retain the Recursion name and continue trading on NASDAQ. 该合并实体旨在通过利用人工智能、精密化学设计和自动化合成技术加速发现和翻译优质药品。 The merged entity aims to accelerate the discovery and translation of high-quality medicines by leveraging AI, precision chemistry design, and automated synthesis technologies. 预计联合公司将在今后18个月中宣读大约10个临床试验,每年可能达到10亿美元的高峰销售机会。 The combined company is expected to read out approximately ten clinical trials in the next 18 months, with potential peak sales opportunities of over $1 billion annually. 合并将产生每年约1亿美元的协同效应,并将公司跑道延长到2027年。 The merger will result in approximately $100 million in annual synergies and extend the company's runway into 2027. 联合公司将重点关注肿瘤学、罕见疾病和传染病等范围内的一流和一流最佳药物候选者。 The combined company will focus on first-in-class and best-in-class drug candidates within oncology, rare disease, and infectious disease.